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Context: Subclinical hypercortisolism (SH) is a condition of biochemical cortisol excess without the
classical signsorsymptomsofoverthypercortisolism. It is thoughttobepresent inthe5–30%ofpatients
with incidentally discovered adrenal mass (adrenal incidentalomas), which in turn are found in 4–7%
of the adult population. Therefore, SH has been suggested to be present in 0.2–2.0% of the adult
population. Some studies suggested that this condition is present in 1–10% of patients with diabetes
or established osteoporosis. The present manuscript reviews the literature on diagnostic procedures
and the metabolic effect of the recovery from SH.
Evidence Acquisition: A PubMed search was used to identify the available studies. The most rel-
evant studies from 1992 to November 2010 have been included in the review.
Evidence Synthesis: The available data suggest that SH may be associated with chronic complica-
tions, such as hypertension, diabetesmellitus, overweight/obesity, and osteoporosis. The available
intervention studies suggest that the recovery from SH may lead to the improvement of hyper-
tension and diabetes mellitus. A retrospective study suggests that this beneficial effect could be
predicted before surgery.
Conclusions: SH is suggested to be associated with some chronic complications of overt cortisol
excess. Recovery from this condition seems to improve these complications. However, a large,
prospective, randomized study is needed to confirm this hypothesis and to establish the best
diagnostic approach to identify patients with adrenal incidentalomas who can benefit from
surgery. (J Clin Endocrinol Metab 96: 1223–1236, 2011)
Subclinical hypercortisolism (SH) is defined as a statusof altered hypothalamic-pituitary-adrenal (HPA)
axis secretion in the absence of the classical signs or symp-
toms of overt cortisol excess (1, 2). The diagnosis and
treatment of SH have recently become a topic of growing
interest and are currently under debate (3, 4). The interest
in SH is due to its high prevalence. Indeed, SH is estimated
to be present in 5–30% of patients with adrenal masses
serendipitously found by imaging for unrelated diseases
[adrenal incidentalomas (AI)] (1, 5). Because AI are
thought to be present in up to 4–7% of adults (6–11), the
prevalence of SH in this populationmaybe estimated to be
between 0.2 and 2.0% (2).
The term “subclinical hypercortisolism” has been pre-
ferred to that of “preclinical” or “subclinical Cushing syn-
drome” because the progression toward overt clinical hy-
percortisolism is very rare (11–13). However, although
SH by definition is not associated with signs and/or symp-
toms specific to overt cortisol excess, such as purple striae,
easy bruising, proximal muscle weakness, and plethora
(14), some evidence suggests that this condition may lead
to long-term consequences of cortisol excess (i.e. diabetes,
hypertension, obesity, and osteoporosis) (15–21). These
conditions, however, are not specific to cortisol excess,
being highly frequent in the general population. Thus,
even if the concomitant presence in the same individual of
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all these possible consequences of cortisol excessmay sug-
gest the presence of SH, in the absence of specific signs or
symptoms of hypercortisolism but in the presence of bio-
chemical abnormalities ofHPAaxis, the term“subclinical
hypercortisolism” may be adequate.
This clinical review will summarize the available data
regarding the diagnostic approach, prevalence, and man-
agement of SH.
Diagnosis of SH
Pitfalls in the diagnosis of SH
Although the above-reported definition of SH is ex-
tensively used and accepted, there is no consensus yet on
the clinical and/or biochemical criteria to diagnose this
condition.
The diagnosis of SH is a challenge for clinicians due to
several causes. First, particularly in AI patients, cortisol
secretion is a continuum from completely normal to
clearly increased levels, and it is highly variable in the same
individual (3, 22). Therefore, diagnosing SH by arbitrary
cutoffs of indexes of cortisol secretion leads to unavoid-
able mistakes in classifying some patients.
Second, the reliability of almost all markers of HPA
axis activity, particularly ACTH and 24-h urinary free
cortisol (UFC), is low (3, 14, 23), and several comor-
bidities (i.e. type 2 diabetes and obesity) and concom-
itant medications may affect the result of the dexameth-
asone suppression test (DST) (24).
Finally, because SH by definition is not characterized by
a specific clinical picture, a clinical “gold standard” for di-
agnosing SH is lacking. As a consequence, the identification
of subtle signs of cortisol excess depends mainly on the per-
sonal practice of the physician and may, therefore, be over-
looked by those with less expertise with hypercortisolemic
patients. However, in our and other authors’ experience (1),
the presence of signs and/or symptoms of cortisol excess is
extremely rare in patients referred for the presence of an AI.
On the other hand, it has become increasingly evident that
theglucocorticoid sensitivitymaybedifferent among thedif-
ferent individuals andamong thedifferent tissues in the same
individual, due also to polymorphisms of both glucocorti-
coid receptor (25–28) and 11-hydroxysteroid-dehydroge-
nase type 1 genes (29, 30).
Alterations of HPA axis activity parameters in
patients with AI
Themajority of the studies regarding the diagnosis and
the treatment of SHhave been focusedon series of patients
with AI. The above-mentioned pitfalls explain the discor-
dant data about the prevalence of SH in these patients (9,
17–19, 21, 22, 31–62). Several alterations of HPA axis
secretion have been reported in AI patients, whose fre-
quencies vary among the different series. In more than
25% of AI subjects, the lack of cortisol suppression after
1- or 3-mg overnight DST or 2-d low-dose DST (LDDST)
(19, 34, 41, 44, 46, 48, 53, 55, 56, 60, 61), elevated UFC
levels (21, 43, 48, 49, 53, 60, 63), loss of cortisol secretion
circadian rhythm (22, 44, 48, 56, 60), altered cortisol and
ACTH response to CRH stimulation (37, 38, 46), low
basal ACTH (19, 21, 32, 36, 40, 43, 44, 48, 49, 56, 60,
61), and dehydroepiandrosterone sulfate (DHEAS) (35–
38, 41) levels are present, suggesting the presence of SH
(Table 1).
The frequency of altered 1-mg or 3-mg DST in AI pa-
tients varies among the different studies, ranging from 3.0
to 100% on the basis of the cutoff, dexamethasone doses,
and modality of execution (Table 1). To date, the 1-mg
DST is the most used test to diagnose SH, either alone
(34–36, 38, 44–46) or in combination with other param-
eters (9, 18, 21, 32, 37, 39, 42, 49, 52–54, 56, 60, 61).
Nonetheless, the 1-mg DST cutoff is still a matter of de-
bate. The National Institutes of Health State-of-the-Sci-
ence Conference (64) and the American Association of
Clinical Endocrinologists and American Association of
Endocrine Surgeons Medical Guidelines for the Manage-
ment of AI (65) recommend the cutoff of 5 g/dl (138
nmol/liter) as the normal level of cortisol suppression in
patients with suspected SH. The reason to screen for SH
with a higher cutoff than that recommended for overt cor-
tisol excess [1.8 g/dl (50 nmol/liter)] (66) is that in pa-
tients without signs or symptoms suggestive of hypercor-
tisolism, the a priori possibility of having SH is estimated
to be lower than that of a false-positive result (1). Thus,
reducing the cutoff of 1-mg DST leads to a decrease in
specificity and, therefore, to more false diagnosis of SH
(65). Several studies (19, 21, 32, 34, 38, 39, 44, 46, 49, 53,
60, 61, 67) and recently the French Society for Endocri-
nology (68), however, have proposed a lower cutoff to
increase sensitivity. On the contrary, to increase specific-
ity, some authors have proposed higher (3 or 8 mg) dexa-
methasone doses (40, 46, 54, 56), which however did not
showabetter performance (14, 23, 66). Similarly, LDDST
has been used to diagnose SH (18, 40, 41, 55) without
advantages, with the exception of patients affected with
alcoholism, psychiatric disorders, and diabetes in whom
this testmaybemore accurate (1, 14, 66). BecauseLDDST
is cumbersomeandnot easy tobeperformed, it is generally
used as a confirmatory test (1, 14). In the author’s opinion,
the use of the cutoff of 3.0 g/dl (83 nmol/liter) for the
1-mg DST test represents the best compromise between
sensitivity and specificity for screening for SH because it
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has been substantiated on a clinical basis (19, 21, 32, 34,
44, 46, 48, 49, 53, 56, 58–61).
Few studies reported a high frequency (i.e. higher than
25%) of elevated UFC levels in patients with AI (21, 43,
48, 49, 53, 60). Generally, UFC is used in combination
with other parameters to individuate patients with SH (9,
18, 19, 21, 32, 37, 42, 47, 49, 52, 53, 60, 61). This may
be because UFC cannot reliably reveal a slight cortisol
TABLE 1. Alterations of the HPA axis secretion in patients with AI
First author, year (Ref.)
No. of
patients
CRH
(%)
CCR
(%)
ACTH
(%)
UFC
(%)
DST
(%) DEX dose, DST cutoff SH criteria
SH
(%)
Reincke, 1992 (34) 68 7.5 n.a 11.8 4.4 21.6 1 mg, 3 g/dl DST 12
Osella, 1994 (35) 45 22 n.a n.a. 2 15 1 mg, 5 g/dl DST 16
Flecchia, 1995 (36) 24 n.a. n.a 25 21 17 1 mg, 5 g/dl DST 29
Ambrosi, 1995 (37) 32 33 n.a. 12.5 12.5 13.7 1 mg, 5 g/dl DST plus 1 out
of CRH, CCR,
ACTH, UFC
12
Bardet, 1996 (38) 35 33 n.a. 21 11 13 1 mg, 3.5 g/dl DST 8.5
Bondanelli, 1997 (39) 38 8 n.a. 18 2.6 10 1 mg, 3.5 g/dl DST plus ACTH 10.5
Kasperlik-Zeluska, 1997 (40) 208 17 n.a. 34 5.2 3a LDDST, 2 mg/24 ha DST plus HDDST 2.9
Tsagarakis, 1998 (41) 61 n.a. n.a n.a. n.a. 25 LDDST, 2.5 g/dl DST 25
Terzolo, 1998 (42) 53 n.a. n.a. 9.4 7.5 17 1 mg, 5 g/dl DST plus UFC 6
Torlontano, 1999 (43) 32 n.a. n.a. 65.6 25 9.4 1 mg, 5 g/dl UFC 25
Rossi, 2000 (18) 65 n.a. 12.3 23 17 25 LDDST, 3.0 g/dl DST plus 1 out
of CRH, CCR,
ACTH, UFC
18.5
Mantero, 2000 (9) 1004 17 17 15 11 10 1 mg, 5 g/dl 2 out of CRH,
CCR, ACTH,
UFC, DST
9.2
Favia, 2000 (45) 158 n.a. n.a. n.a. n.a. 5.1 1 mg, 5 g/dl DSTc 5.1
Tanabe, 2001 (44) 38 13.1 28.9 26 n.a. 47.4 1 mg, 3 g/dl DST 47.4
Midorikawa, 2001 (46) 15 26.6 6.6 15 n.a. 26.6 1 mg, 3 g/dl DST or HDDST 26.6
Grossrubatscher, 2001 (47) 53 n.a. n.a. 15 4a 11 1 mg, 5 g/dl DST plus 1 out
of CRH, CCR,
ACTH, UFC
5.7
Valli, 2001 (48) 31 n.a. 25.8 25.8 61 38.4 1 mg, 5 g/dl Unilateral uptaked 61.3
Chiodini, 2001 (49) 24 n.a. n.a. 41.7 33.3 12.5 1 mg, 3 g/dl 2 out of ACTH,
UFC, DST
29
Libè, 2002 (52) 64 4.6 n.a. 10.9 9.4 18.7 1 mg, 5 g/dl 2 out of CRH,
CCR, ACTH,
UFC, DST
18.8
Chiodini, 2002 (53) 38 n.a. n.a. 23.7 42.1 28.9 1 mg, 3 g/dl 2 out of ACTH,
UFC, DST
34.2
Emral, 2003 (54) 70 n.a. n.a. n.a. n.a. 5.7 3 mg, 3 g/dl DST and HDDST 5.7
Hadjidakis, 2003 (55) 42 n.a. n.a. n.a. n.a. 43 LDDST, 2.5 g/dl LDDST 42.9
Chiodini, 2004 (19)b 70 n.a. n.a. 57.1 20 28.5 1 mg, 3 g/dl 2 out of ACTH,
UFC, DST
30
Katabami, 2005 (56) 39 n.a. 73.5 46.6 n.a. 38.5 1 mg, 3 g/dl DST and HDDST 38.5
Terzolo, 2005 (22) 210 n.a. 29.4 9.7 10.8 13.8 1 mg, 5 g/dl n.a. n.a.
Chiodini, 2009 (21)b 287 n.a. n.a. 26.4 52.9 24.7 1 mg, 3 g/dl 2 out of ACTH,
UFC, DST
29.6
Masserini, 2009 (32)b 103 n.a. 14.6 50.5 12.6 24.3 1 mg, 3 g/dl 2 out of ACTH,
UFC, DST
21.4
Eller-Vainicher, 2010 (60)b 60 n.a. 48.3 63.3 31.7 53.3 1 mg, 3 g/dl 3 out of CCR,
ACTH, UFC,
DST
48.3
Chiodini, 2010 (61)b 108 n.a. n.a. 52.8 20 28.7 1 mg, 3 g/dl 2 out of ACTH,
UFC, DST
38
CRH, Blunted response to CRH; CCR, altered circadian cortisol rhythm (elevated MSeC or MSaC levels); ACTH, low ACTH levels 10 pg/ml (2.2
pmol/liter); UFC, 24-h UFC levels above the upper limit of the normal range; DST, reduced cortisol suppression after a DST; DEX, dexamethasone;
HDDST, high dose (8 mg) overnight DST; LDDST, 2-d low dose (2 mg/d) DST; n.a., data not available. SI conversion factors: cortisol  27.56;
ACTH  0.22.
a 24-h urinary 17-hydroxycorticosteroids.
b Data provided by the authors but not reported in the papers.
c DST was performed in patients with increased morning serum cortisol levels.
d 131I-6b-iodomethyl norcholesterol scintigraphy.
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excess (69, 70) and may also be due to the technical prob-
lems associated with its determination (14, 69–73).
Therefore, UFC should not be considered an adequate
screening test for SH and should be used in combination
with other tests or in specific populations (1, 14).
Several authors reported the presence of an altered cir-
cadian cortisol secretion rhythm in AI patients with high
midnight cortisol levels (22, 44, 48, 56, 60). Even if mid-
night serumcortisol (MSeC) has been shown tobe a prom-
ising tool for diagnosing SH (22), its use is limited by the
need of the hospital admission for the cumbersome pro-
cedure, and it could be used as a confirmative test in se-
lected patients (60). The possible use of midnight salivary
cortisol (MSaC),which ismore feasible and less expensive,
is still debated (73, 74). Some authors found a low sensi-
tivity of MSaC in identifying SH (31, 32), whereas others
showed that subjects with either consistent or frequent
elevations of this parameter may actually have SH (69). In
fact, the various studies on the diagnostic accuracy of the
different salivary cortisol assaysarehardly comparable for
differences in the patients’ and controls’ selection criteria
and in the diagnostic performance and sample collection
techniques of the various laboratory methods (75). Thus,
this test should not be used for diagnosing SHuntil further
studies and a standardization of the laboratory methods
are available.
Low serum ACTH levels are frequently found in AI
patients (19, 21, 32, 36, 40, 43, 44, 48, 49, 56, 60, 61).
Because ACTH is generally low in patients with ACTH-
independent overt cortisol excess (14), this parameter has
alsobeenproposed for diagnosing SH (1, 9, 39).However,
because ACTH may be normal even in patients with
ACTH-independent overt cortisol excess, the role of low
ACTH levels in diagnosing SH is questioned (23). There-
fore, ACTH alone does not seem sensitive enough for di-
agnosing SH. The determination of ACTH levels after
CRH does not seem to add any advantage (1, 23, 34, 35,
37, 38, 46) to screening for SH.However,measuring basal
and CRH-stimulated ACTH levels in AI patients with es-
tablished SH helps to avoid missing a possible ACTH-
dependent origin of the cortisol excess. Indeed, monolat-
eral or bilateral adrenal enlargement is frequent inpatients
with an ACTH hypersecretion. Therefore, in AI patients
with a strong suspicion of cortisol excess, even if subclin-
ical, the presence of not suppressed basal ACTH levels
should push the clinician to exclude the presence of a pi-
tuitary or ectopic ACTH hypersecretion. In particular,
ACTH levels above 20 pg/ml (4.4 pmol/liter) or below 10
pg/ml (2.2 pmol/liter) suggest anACTH-dependent or -in-
dependent cause of SH, respectively (66). A CRH-stimu-
lated ACTHdetermination is useful in those subjects with
baseline ACTH levels between 10 and 20 pg/ml (2.2–4.4
pmol/liter). In these patients, an ACTH peak below 30
pg/ml (6.6 pmol/liter) after CRH excludes the presence of
an ACTH-dependent SH (76).
Low serum DHEAS levels are one of the most fre-
quent HPA axis alterations in AI patients (35–38, 41).
Although it may reflect an autonomous ACTH-inde-
pendent cortisol hypersecretion, available data do not
demonstrate that low DHEAS concentration is a reli-
able index of SH (1, 23, 35), also considering that
DHEAS levels decrease with age (77).
Because the increase in sensitivity is accompanied by
the decrease in specificity with the lowering of the 1-mg
DST cutoff and vice versa, the combination of different
parameters of HPA axis activity has been proposed to
increase specificity without affecting sensitivity. In a sem-
inal paper, Terzolo et al. (42) proposed the use of different
combinations of several different parameters (i.e. high
UFC levels, cortisol levels after 1-mg DST, high average
daily serum cortisol, altered circadian cortisol rhythm,
low basal ACTH levels, or blunted ACTH response to
CRH) to screen for SH and the terms “definitive SH,”
“probable SH,” and “possible SH”. To simplify the diag-
nostic workout, other authors used the concomitant pres-
enceof at least twoalteredparameters ofHPAaxis activity
for SH diagnosis (9, 18, 19, 21, 32, 37, 39, 40, 42, 47, 49,
52–54, 56, 60, 61).
Diagnostic accuracy of the different approaches
for diagnosing SH
A few studies (summarized in Table 2) evaluated the
sensitivity and specificity of the different HPA axis pa-
rametersor combinationofparameters fordiagnosingSH.
The difficulty in performing such studies is due to the lack
of a clinical, biochemical, or functional parameter that can
be used as the gold standard. Some studies evaluated the
diagnostic accuracy of the various parameters ofHPAaxis
secretion using arbitrarily defined biochemical criteria (9,
31, 32, 52) as the gold standard. Overall, in these studies,
the different parameters showed a good specificity (90–
98%, using 1-mg DST) but, generally, a poor sensitivity
(41–86% using ACTH levels). The altered circadian
rhythm, evaluated by either MSaC or MSeC, and UFC
levelswerenot found tobe sensitive enough fordiagnosing
SH (31, 32). However, these results have been biased by
the fact that the biochemical gold-standard criteria used to
define SH had not been previously validated.
To overcome this limitation, some studies investigated
the accuracy of 1-mgDST for diagnosing SH inAI patients
using the unilateral concordant uptake of radiotracer by
iodocholesterol scintigraphy as the gold standard (48, 67).
Using the highest cutoff [5 g/dl (138 nmol/liter)], 1-mg
DST was confirmed to have good specificity (83–100%)
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but low sensitivity (44–58%). However, if the lowest cut-
offs were used [1.8 and 2.2g/dl (50 and 60.6 nmol/liter),
respectively], specificity decreased to 67–72%, whereas
sensitivity increased to 75–100% (48–62, 64–67). The
1-mg DST cutoff of 3.0 g/dl (83 nmol/liter) showed the
best compromise between sensitivity (63%) and specific-
ity (75%) (48). The main pitfall of these studies is that the
increased uptake of the radiotracer may simply reflect the
presence of enlarged adrenal tissue rather than an in-
creased cortisol secretion (1, 35, 78). Because this tech-
nique is expensive, time-consuming, and not widely avail-
able, it should be reserved for patientswith still discordant
biochemical data after an adequate follow-up (79, 80).
Another approach to validate the biochemical criteria
for SH may be based on the association between the pa-
rameters of HPA axis activity and the clinical features of
the patients with possible subtle cortisol excess. The oc-
currence of hypocortisolism after the removal of an adre-
nal adenoma has been proposed as the gold standard for
diagnosing SH (58). In a study of 60 AI patients, we eval-
uated the accuracy of the HPA axis secretion parameters
measured before surgery in predicting the occurrence of
postsurgical hypocortisolism (58). We found that the si-
multaneous presence of elevated UFC and MSeC levels
[5.4 g/dl (149 nmol/liter)] before surgery had a 100%
specificity for predicting postsurgical hypocortisolism,
but at the expense of a 30.8% sensitivity. Also in this
study, lowering the cutoff of 1-mgDSTwas demonstrated
to lead to a reduction in specificity (from 85.7 to 23.8%)
and an increase in sensitivity (from33.3 to 79.5%).More-
over, after excluding MSeC, all combinations of the re-
maining parameters did not show enough reliability for
predicting hypocortisolism after surgery, and conversely,
the normality of all parameters ofHPAaxis activity before
surgery could not rule out with 100% probability the ap-
pearance of postsurgical adrenal insufficiency. The main
criticism to this approach for diagnosing SH is that post-
surgical hypocortisolism reflects only the pituitary sensi-
TABLE 2. Accuracy of HPA axis secretion parameters in diagnosing SH
First author, year
(Ref.)
No. of
patients
CCR
(SN/SP)
ACTH
(SN/SP)
UFC
(SN/SP)
DST
(SN/SP)
DEX dose,
DST cutoff
Gold standard criteria for
SH diagnosis
Mantero, 2000 (9) 1004 43/83 79/85 76/88 73/90 1 mg, 5 g/dl 2 out of CRH, CCR, ACTH,
UFC, DST
Libè 2002 (52) 64 n.a. 41/96 33/96 91/98 1 mg, 5 g/dl 2 out of CRH, CCR, ACTH,
UFC, DST
Masserini, 2009
(32)
103 22.7/87.7 86.4/59.3 31.8/92.6 86.4/96.3 1 mg, 3 g/dl 2 out of DST, ACTH, UFC
Nunes, 2009 (31) 48 77/69a n.a. n.a. n.a. 1 mg, 2.2 g/dl DST plus ACTH or CCR
77/68b 1 mg, 2.2 g/dl DST plus ACTH or CCR
Barzon, 2001 (67) 83 n.a. n.a. n.a. 44/100 1 mg, 5 g/dl Norcholesterol scintigraphy
75/72 1 mg, 1.8 g/dl Norcholesterol scintigraphy
Valli, 2001 (48) 31 n.a. n.a. n.a. 58/83 1 mg, 5 g/dl Norcholesterol scintigraphy
63/75 1 mg, 3 g/dl Norcholesterol scintigraphy
100/67 1 mg, 2.2 g/dl Norcholesterol scintigraphy
Eller-Vainicher,
2009 (58)
60 64.1/81d 64.1/38 48.7/81 33.3/85.7 1 mg, 5 g/dl Postsurgical hypocortisolism
59/52.4 1 mg, 3 g/dl Postsurgical hypocortisolism
79.5/23.8 1 mg, 1.8 g/dl Postsurgical hypocortisolism
Morelli, 2010 (59) 231 n.a. 52.4/60.5 42.9/80 23.8/93.3 1 mg, 5 g/dl Prevalence of complicationse
52.4/81.4 1 mg, 3 g/dl Prevalence of complicationse
71.4/49.5 1 mg, 1.8 g/dl Prevalence of complicationse
Eller-Vainicher 2010
(60)
55 65.2/65.6c n.a. n.a. 21.7/96.9 1 mg, 5 g/dl Metabolic improvement
after surgeryf
91.3/56.3 1 mg, 2.0 g/dl Metabolic improvement
after surgeryf
CRH, Blunted response to CRH; CCR, altered circadian cortisol rhythm (elevated MSeC or MSaC levels); ACTH, low ACTH levels 10 pg/ml (2.2
pmol/liter); UFC, 24-h UFC levels above the upper limit of the normal range; DST, reduced cortisol suppression after a DST; DEX, dexamethasone;
n.a., data not available; SN, sensitivity (%); SP, specificity (%).
a MSaC levels cutoff, 1.7 g/liter (47 nmol/liter).
b MSeC levels cutoff, 4.9 g/dl (135 nmol/liter).
c MSeC cutoff, 4.0 g/dl (110 nmol/liter).
d MSeC cutoff, 5.4 g/dl (149 nmol/liter).
e Concomitant presence of vertebral fractures, arterial hypertension, and type 2 diabetes mellitus.
f Improvement after surgery of at least two out of the following possible complications of SH: blood pressure, fasting glucose, body weight, and
cholesterol levels.
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tivity to cortisol excess and not that at the peripheral tis-
sues (25–30).
Another clinical approach to validate the different cri-
teria for diagnosing SH is to evaluate their association
with the simultaneous presence of the possible complica-
tions of cortisol excess such as osteoporosis, diabetes mel-
litus, and hypertension. In the study by Morelli et al. (59)
on 231 AI patients, the presence of a combination criterion
characterized by the presence of at least two biochemical
alterations among 1-mg DST above 3 g/dl (83 nmol/liter),
elevatedUFC, andACTHbelow 10 pg/ml (2.2 pmol/liter)
(DST-UFC-ACTH combination criterion) showed the best
balancebetweensensitivity (61.9%)andspecificity (77.1%),
reaching an acceptable accuracy (75.8%) in predicting the
cluster of complications. This study confirmed the low sen-
sitivity and specificity of 1-mg DST when the high or low
cutoff, respectively, is used and the low accuracy of the re-
duced ACTH and increased UFC level, when used as single
criterion (59). The limit of this approach is that these com-
plications (i.e.osteoporosis, diabetesmellitus, andhyperten-
sion) are not specific for cortisol excess, being highly preva-
lent in thegeneral population.Moreover, theuseof theDST-
UFC-ACTHcombinationcriterion is limited to thediagnosis
of SH of adrenal origin because ACTH levels are useless in
patients with suspected ACTH-dependent SH.
In a recent retrospective study, we tested in surgically
(n 55) or conservatively (n 33) treated AI patients the
accuracy for diagnosing SH of various HPA axis param-
eters using the changes in blood pressure, cholesterol lev-
els, body weight, and fasting glucose after AI removal as
the possible gold standard for defining SH (60). The DST-
UFC-ACTH combination criterion was confirmed to be
useful because it showed the best accuracy in predicting
improvement (sensitivity, 65.2%; specificity, 68.8%) in
surgically treated patients andworsening of the endpoints
(sensitivity, 55.6%; specificity, 82.9%), in the conserva-
tively treated subjects.
In summary, all studies specifically designed for indi-
viduating the best criterion for diagnosing SHshowed that
no single parameter has, in fact, an adequate sensitivity
and specificity. In the absence of a clear and widely ac-
cepted gold standard and of more reliable methods for
assessing cortisol secretion (particularly for the ACTH
and UFC measurement), the diagnosis of SH remains a
challenge for physicians.However, to date, theDST-UFC-
ACTH combination criterion seems the best compromise
to diagnose SH because it has been validated on a clinical
basis (32, 59, 60).
Prevalence of SH and of Its Different
Causes
Several studies suggest that SH is likely to be underre-
ported. It is known that diabetesmellitus andosteoporosis
are frequently found in patients with cortisol excess. Be-
cause in past years several studies have shown that SHmay
also be associated with a high risk of osteoporotic frac-
tures and metabolic consequences (15–22), it has been
hypothesized that in populations of diabetic and osteopo-
rotic patients the prevalence of SH would be higher than
in healthy subjects (Table 3).
In a cross-sectional study on 90 obese diabetic patients
with poormetabolic control, Leibowitz et al. (63) found a
3.3% prevalence of SH due to an adrenal adenoma in one
patient and a pituitary adenoma in two patients using
1-mg DST above 5.1 g/dl (140 nmol/liter) as a screening
test. This finding was confirmed in a study showing the
presence of one case of pituitary SH in a sample of 48
overweight diabetics (81). In a larger study of a similar
population using 1-mg DST as a screening test with a
lower and, therefore, more sensitive cutoff, SHwas ascer-
tained in four (three of pituitary and one of adrenal origin)
of 200 diabetic patients studied (2.0% prevalence) (82).
TABLE 3. Studies investigating the prevalence of SH and its origin in type 2 diabetic and osteoporotic patients
First author,
year (Ref.) Population (n)
Screening
test Cutoff
Overall
prevalence (%)
Adrenal
origin (%)
Pituitary
origin (%)
Other
origin (%)
Leibowitz, 1996 (63) Type 2 diabetics (90) 1-mg DST 5.1 g/dl 3.3 33.3 66.6 0
Contreras 2000 (81) Type 2 diabetics (48) UFC 112 g/24 h 2.1 0 100 0
1-mg DST 1.4 g/dl
Kann, 2001 (90) Osteoporotics (78) 3-mg DST 1.8 g/dl 3.8 100 0 0
Catargi, 2003 (82) Type 2 diabetics (200) 1-mg DST 2.1 g/dl 5.5 72.3 27.3 0
Chiodini, 2005 (83) Type 2 diabetics (294) 1-mg DST 1.8 g/dl 10.8 66.6 13 20.4
Liu, 2005 (88) Type 2 diabetics (154) MSaC 0.15 g/dl 0 0 0 0
Reimondo, 2007 (85) Type 2 diabetics (100) 1-mg DST 3.6 g/dl 1 0 100 0
Chiodini, 2007 (91) Osteoporotics (147) 1-mg DST 1.8 g/dl 4.8 85.4 14.6 0
Newsome, 2008 (86) Type 2 diabetics (178) 1-mg DST 1.8 g/dl 0 0 0 0
Taniguchi, 2008 (84) Type 2 diabetics (77) MSeC 5.0 g/dl 2.6 0 100 0
Mullan, 2010 (87) Type 2 diabetics (201) MSaC 0.4 g/dl 0 0 0 0
UFC, 24-h UFC. SI conversion factor: cortisol  27.56.
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However, SHwas very likely in seven additional subjects.
Overall in this study, the prevalence of SH could be esti-
mated to be almost 5.5%, with a pituitary and adrenal
origin of 1.5 and 4.0%, respectively. These datawere con-
firmed in a similar controlled study on 294 diabetic inpa-
tients inwhoma 10.8%prevalence of SHwas found,with
pituitary, adrenal, and undefined/ectopic origin account-
ing for 1.4, 7.2, and 2.2%, respectively (83). In keeping
with this, Taniguchi et al. (84) found a 2.6%prevalence of
SH in a sample of 77 inpatients with type 2 diabetes. Di-
agnosis was done by measuring MSeC using a cutoff of 5
g/dl (138 nmol/liter). However, these figures were par-
tially different in the study of Reimondo et al. (85), in
which only one of 100 patients with newly diagnosed di-
abeteswas found to have a pituitary-dependent SH. In this
study, however, a high cutoff for 1-mg DST was used.
Other authors failed to detect patients with SH in the
populations at risk (86–88). By using 1-mg DST as a
screening test with a low cutoff in a sample of 178 diabetic
patients,Newsome et al. (86) did not find any subjectwith
SH. Similarly, by using MSaC, a poor test for screening
SH, two studies did not detect SH in more than 150 over-
weight/obese diabetic patients (87, 88). Besides the differ-
ent cutoffs or screening tests used, these discordancesmay
be related to the different populations studied (i.e. outpa-
tients or inpatients, patients with poorly or well-con-
trolled diabetes).
An unexpected high prevalence of SH has also been
reported in patients with osteoporosis. Indeed, it is well
known that vertebral fractures may be the presenting
symptoms of an otherwise asymptomatic cortisol excess,
and several case reports have been reviewed recently (89).
However, data regarding the prevalence of SH in osteo-
porosis are scarce. In assessing theHPA axis by 3-mgDST
with a sensitive cutoff, a 3.8% prevalence of SH was
found; all cases were of adrenal origin (90). A subsequent
study from our group onmore than 200 patients using the
same screening test showed that SH was present in 4.8%
of patients with osteoporosis and 10.8% of patients with
osteoporosis and vertebral fractures. In this study, SHwas
of adrenal andpituitary origin in4.1 and0.7%ofpatients,
respectively (91).
These studies suggest that SH may be more frequent
in patientswith diabetes and osteoporosis, thus explain-
ing the increased fracture risk. Moreover, in reducing
the cutoff of the screening test and therefore increasing
its sensitivity, the adrenal cause of SH became more
frequent than the pituitary cause. Overall, from the
available data regarding the screening of the population
at risk for SH (diabetics and osteoporotics), it comes
evident that, unlike the condition of overt cortisol ex-
cess, the condition of SH is more commonly of adrenal
origin. However, no data are available regarding the
prevalence of subclinical ACTH hypersecretion in pa-
tients with pituitary incidentalomas (92).
The usefulness of the screening of SH in the popula-
tions at risk clearly depends on the possible SH-associ-
ated increased morbidity and mortality, which are still
unknown. Moreover, because the a priori possibility of
having SH is estimated to be lower than that of a false-
positive result (1), the economic costs of the screening
for SHwould probably be elevated. To date, no data are
available on the cost effectiveness of the screening of the
populations at risk.However, it seems rational to screen
for SH all patients with very low bone mineral density
and/or vertebral fractures without other known second-
ary causes of osteoporosis (91) and type 2 diabetes pa-
tients with poor metabolic control despite an adequate
diet, lifestyle, and pharmacological treatment—in par-
ticular those simultaneously affected with osteoporosis
and hypertension (59).
Therapy of SH
Theavailable studies regarding the clinical effects of the
recovery from SH considered the improvement of its pos-
sible metabolic consequences (i.e. diabetes, hypertension,
and obesity) as endpoints (18, 46, 54, 61, 93–97). Unfor-
tunately, to date, no large prospective randomized trial
compared the effect of surgical vs. conservative treat-
ment in patients with SH (Table 4). The only available
prospective randomized study found in 23 surgically
treated subjects improvement of hypertension, diabe-
tes, obesity, and dyslipidemia in 66.7, 62.5, 50, and
37.5%of cases, respectively (57). On the contrary, in 22
conservatively treated patients, hypertension, diabetes,
and dyslipidemia worsened in 80, 33.3, and 20% of
cases (57). However, in this study, a direct comparison
of the changes of the endpoints between the two groups
was not done. Nonetheless, as observed by the authors,
these data suggest that surgical treatment is more ben-
eficial than conservative treatment (57).
In keeping with these data, previous prospective, non-
randomized studies found similar results (18, 46, 54, 93–
96). Rossi et al. (18) found that blood pressure and dia-
betes improved in 100 and 60% of five surgically treated
SHpatients, respectively,whereas no changeswere seen in
seven conservatively treated SH subjects. A subsequent
study of 10 subjects found after recovery from SH an im-
provement of blood pressure, metabolic control of diabe-
tes, and dyslipidemia in 83, 22, and 67% of cases, respec-
tively, whereas in 12 conservatively treated subjects,
hypertension, diabetes, and obesity worsened in 17, 25,
and 17% of cases, respectively (96). Several small studies
suggested the improvement of blood pressure (54, 93, 95),
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glucosemetabolism (46, 54, 93, 95), and bodyweight (54,
95) in surgically treated SH patients. In a retrospective,
nonrandomized study, we reported that in 25 surgically
treated SHpatients, bodyweight, blood pressure, and glu-
cose levels improved (32, 56, and 48%, respectively)more
frequently than in untreated SH subjects (12.5, 0.0, and
0.0%, respectively) (61). On the contrary, in surgically
untreated SH patients, blood pressure, glucose, and cho-
lesterol levels worsened more frequently (50.0, 37.5, and
50.0%, respectively) than in surgically treated patients (0,
0, and 24%, respectively) (61). Although surgically
treated patients were younger than conservatively treated
TABLE 4. Studies investigating the effect of the recovery from SH on blood pressure, body weight, fasting glucose,
and bone
First author, year
(Ref.) Design
SH SH
FU
(months) SH criteria BP BW FG Bone
Surg
(n)
Cons
(n)
Surg
(n)
Cons
(n)
Rossi, 2000, (18) Prosp. 5 7 13 25 18–300 Cortisol 5.0 g/dl after
1-mg DST plus 1 out
of: high UFC, low
ACTH, loss of F
rhythm, blunted ACTH
after CRH
1a – 1a –
Midorikawa, 2001 (46) Prosp. 4 – 8 – 1 Cortisol 3.0 g/dl after
1-mg DST and low
ACTH
8a 2 1a –
Emral, 2003 (54) Prosp. 3 1 3 57 n.a. Cortisol 3.0 g/dl and
UFC reduction  50%
after 3-mg DST
1 1 1 –
Bernini, 2003 (93) Prosp. 6 – 9 – 12 Cortisol 5.0 g/dl after
1-mg DST
1a 2 1a –
Erbil, 2006 (94) Retrosp. 11 – – 83 12 Cortisol 3.0 g/dl after
1-mg DST and 8-mg DST
8 8 8 –
Mitchell, 2007 (95) Retrosp. 9 – – – 1–30 Cortisol 1.0 g/dl after
1-mg DST plus 1 out
of: high UFC, low
ACTH, low DHEAS,
lateralization with AVS,
clinical signs
1 1 1 –
Tsuiki, 2008 (96) Retrosp. 10 12 – – 7–19 Cortisol 3.0 g/dl after
1-mg DST and 1.0
g/dl after 8-mg DST
plus 1 out of: low
ACTH, loss of CCR, low
DHEAS, AS uptake
1 2 8 –
Toniato, 2009 (57) Prosp. Rand. 23 22 – – 24–204 Cortisol 5.0 g/dl after
1-mg DST plus 1 out
of: high UFC, low
ACTH, loss of CCR
rhythm, blunted ACTH
after CRH
1 – 8 2
Sereg, 2009 (97) Retrosp. 5 8 42 70 109  37 Cortisol 3.6 g/dl after
1-mg DST and/or
MSeC 5 g/dl
2 2 2 –
Chiodini, 2010 (61) Retrosp. 25 16 30 37 18–54 2 out of: cortisol 3.0
g/dl after 1-mg DST,
low ACTH, high UFC
1a 1 1 –
SH, Patients with SH; SH	, patients without SH; FU, range of follow-up; Surg, number of surgically treated patients; Cons, number of patients
followed up with conservative approach; BP, blood pressure; BW, body weight; FG, fasting glucose; CCR, altered circadian cortisol rhythm
(elevated MSeC or MSaC levels); low ACTH, ACTH levels 10 pg/ml; high UFC, 24-h UFC levels above the upper limit of the normal range; DST,
reduced cortisol suppression after a DST; Prosp., prospective; Retrosp., retrospective; Rand, randomized; Cortisol, serum cortisol; AVS, adrenal vein
sampling; AS, adrenal scintigraphy; n.a., not available;1, improvement;8, possible improvement;2, stable; –, not evaluated. SI conversion
factors: cortisol  27.56; ACTH  0.22.
a Improvement also in SH-treated subjects.
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patients, the modification of the metabolic endpoints was
independent of age aswell as the presence of hypertension,
diabetes, obesity, and dyslipidemia at baseline (61). At
variance with all the above-mentioned studies, a recent
retrospective study found no difference in hypertension,
diabetes, and obesity between five and eight SH patients
surgically and conservatively treated, respectively (97).
However, it is likely that the high number of patients who
refused to participate in this study have introduced a cru-
cial selection bias.
Importantly, the criteria for defining an improvement
of the possible complications of SH have been different
among the different studies andwere not always reported.
In our study (61), the improvement or worsening of blood
pressure and fasting glucose was defined following the
Guidelines for the Management of Arterial Hypertension
of the European Society of Cardiology and the Adult
Treatment Panel III (ATP III) criteria, respectively, regard-
less of the diagnosis of hypertension or diabetes before or
after surgery. Importantly, studies using similar criteria
were able to show a clear positive effect of surgery on the
metabolic consequences of SH (18, 54, 61, 93, 96, 97).On
the contrary, in those studies in which these criteria were
not used and the endpoint was simply the presence of
hypertension or diabetes before and after surgery, the ef-
fect of recovery from SH on its metabolic consequences
was less impressive (94) or absent (97). Therefore, sum-
marizing the available data, it is likely that in all patients
with SH, and particularly in those with possible SH com-
plications, surgical treatmentmaybeadvantageous.How-
ever, to date, the small sample size of the available studies
and the lack of a large prospective randomized trial could
not allow us to draw any firm conclusion about this point.
Few studies evaluated the accuracy of the SH diagnosis
before surgery to predict the improvement after surgery
and, therefore, to address the treatment of choice in the
individual subject (18, 46, 61, 93). This is of utmost im-
portance because in several studies some of the surgically
treated patients without SH experienced improvement of
somemetabolic endpoints (18, 46, 61, 93). It is possible to
hypothesize that some patients classified as not having SH
had, in fact, a mild degree of cortisol hypersecretion, sug-
gesting that the diagnosis of SH had not been sensitive
enough.
Looking to the above-mentioned retrospective data on
55 surgically treated patients with AI (60), 1-mg DST
greater than 5 g/dl (138 nmol/liter) and less than 2 g/dl
(55nmol/liter) had thebest specificity and sensitivity (96.9
and 91.3%, respectively) for identifying patients that may
improve after surgery. In patientswith 1-mgDSTbetween
these values, the presence ofMSeC greater than 4.0 mg/dl
(110 nmol/liter) or ACTH less than 10.0 pg/ml (2.2 pmol/
liter) combinedwith the presence of at least twometabolic
complications before surgery had a 76% accuracy in pre-
dicting improvement. Using the protocol illustrated in the
study, in more than 80% of cases the improvement after
surgery was correctly predicted before surgery (60). This
study clearly suffers from the limits of the small sample
and of its retrospective and nonrandomized design. How-
ever, it suggests that by combining clinical and biochem-
ical parameters, it could be possible to identify which AI
patient may benefit from surgery.
In the last few years, several non-ACTH factors have
been suggested as possible regulators of steroidogenesis in
adrenal adenomas. Indeed, it has been shown that recep-
tors for several ligands are abnormally expressed at the
membrane of tumoral adrenocortical cells, such as those
for glucose-dependent insulinotropic peptide, catechol-
amine, vasopressin, serotonin, angiotensin II, leptin, and
LH/human chorionic gonadotropin (98–100). Because
these aberrant receptors may be specific pharmacological
targets for controlling cortisol secretion, their detection
deserves particular interest and some protocols have been
developed (99). Indeed, somatostatin analogs have been
used to control food-dependent cortisol hypersecretion
due to the presence of aberrant glucose-dependent insuli-
notropic peptide receptors (100, 101); propranolol has
been proposed in patients with adrenal hypercortisolism
(102) and leuprolide acetate in LH-dependent Cushing’s
syndrome (103). In the future, these pharmacological ap-
proaches may become extremely useful, in particular in
SH patients with bilateral adenomas because in these sub-
jects the excision of the predominant mass is often not
sufficient to control the cortisol excess.
Follow-up of patients with SH
To date, no widely accepted guidelines are available
regarding the most adequate follow-up in patients with
possible or ascertained SH who did not undergo surgery.
The difficulties in defining a protocol are related to the
variability of cortisol secretion in these patients (3, 22)
because even a 2-yr follow-up may be too short to ascer-
tain the presence of SH (79). On the other hand, definitive
data about the risk of transformation of nonfunctioning
nodules to functional tumors are lacking. Although this
risk was reported to be low in patients with adrenal ade-
nomas smaller than 3 cm (3), two studies suggested that in
patients with an adrenal mass more than 2 cm in size, the
estimated cumulative risk of developing SH may vary be-
tween 7 and 47% after 5 yr (50, 52). Until data will be
available from large prospective studies, a reasonable ap-
proach may be to repeat the hormonal screening annually
for 5 yr, measuring 1-mg DST, ACTH, and UFC levels,
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particularly in patients with possible or not clearly ascer-
tained SH.
Similarly, because in some patients with SH not oper-
ated on, bonemineral density, fasting glucose, blood pres-
sure, and cholesterol levels have been shown to worsen
during follow-up (49, 61), a careful monitoring of these
complications and an evaluation of the adequacy of the
medical therapy should be performed annually. In the
presence of a worsening of bone status, and/or hyperten-
sion, and/or diabetes despite adequate treatments, or in
the presence of an increase of cortisol secretion, surgery is
a reasonable option.
Conclusions
Based on the data reported above, it becomes clear that no
agreement exists regardinghowtobiochemicallydiagnose
SH. This is due to the lack of a clinical or functional pa-
rameter to be used as the gold standard to test the diag-
nostic accuracy of the available biochemical parameters.
Moreover, to date, methodological problems exist in re-
liably measuring cortisol secretion. If a clear diagnosis of
SH cannot be made, it is difficult to ascertain the effect of
surgery. Some improvements attributed to surgery could,
in fact, havebeen related tononspecific changes inmedical
treatment/lifestyle and not to the previous surgery. These
uncertainties, in turn, bring into question the real clinical
importance of SH itself and the need of a surgical treat-
ment in these patients instead of the optimization of med-
ical therapy (61). Indeed, in patients with SH the optimi-
zation with strict criteria of the medical treatment of
osteoporosis, hypertension, diabetes, and dyslipidemia
may avoid the development of the clinical consequences of
these complications (i.e. fractures, cardiovascular dis-
eases, etc.). Although no studies have investigated the as-
sociation of SH with “hard” endpoints, such as cardio-
vascular morbidity and mortality, the available data
suggest a possible deleterious role of SH, at least on glu-
cose and bone metabolism and on hypertension, even in
patients adequately followed up with antihypertensive
and antidiabetic medical therapy (61). Moreover, it must
be considered that the optimization of themedical therapy
is not completely free of adverse events and that adrenal
surgery is becoming increasingly safer by endoscopic pro-
cedures. Finally, because patients with SH seem toworsen
if not surgically treated, the economic costsof surgeryhave
to be compared with those of curing the possible conse-
quences of SH (i.e. chronic complications of diabetes and
hypertension, and fractures). In this regard, however, the
major issue is that if SH is present, at least, in 0.2% of the
population, many more adrenal operations will be neces-
sary than those currently performed. Therefore, a benefit
stratification before surgery will need to be accurate.
These considerations point to the need of large, pro-
spective, randomized trials investigating the effect of sur-
gery on the improvement or worsening of the possible
complications of SH. These studies should include both
surgically treated and adequately medically treated pa-
tients with and without SH and should provide for an
adequate follow-up period (at least 3–5 yr). Several sur-
rogate endpoints, such as body weight, blood pressure,
cholesterol, andglucose or glycatedhemoglobin (HbA1C)
levels should be measured. The improvement or worsen-
ing of body weight should be defined by a greater than
5–10% decrease or increase, respectively (104). The im-
provement or worsening of arterial blood pressure should
be defined if the nonhypertensive patients pass from a
prehypertension category to another or the hypertensive
patients from a hypertension grade to another, following
the Guidelines for the Management of Arterial Hyperten-
sion of the European Society of Cardiology (105), or if the
antihypertensive drugs must be reduced/stopped or in-
creased to maintain the therapeutic target, respectively.
Fasting total cholesterol and/or low-density lipoprotein
levels should be considered to be improved if they show a
25 or 30% reduction, respectively (106), or worsened if
they passed from a category to another in agreement with
the ATP III criteria (107). In patients with diabetes, the
improvement/worsening of the glycometabolic control
should be defined by the reduction/increase of at least a
percentage point of HbA1C and/or by the achievement/
loss of the recommended targets [HbA1C7%; prepran-
dial capillary plasma glucose between 70 and 130 mg/dl
(3.9–7.2 mmol/liter); peak postprandial plasma glucose
80 mg/dl (10 mmol/liter] or if the antidiabetic drugs
must be reduced/stopped or increased (108). In patients
without diabetes, the therapeutic targets should be a
HbA1C below 6.5%, a fasting plasma glucose level below
100 mg/dl (5.6 mmol/liter), and a plasma glucose value
after a 75-g oral glucose tolerance test below 140 mg/dl
(7.8 mmol/liter) (108). The improvement/worsening of
bone mineral density should be defined in the presence of
at least a 3.5% increase/decrease during the follow-up
period (109).
Moreover, studies with an even longer follow-up (i.e.
10 yr) could evaluate the effects of the surgical or conser-
vative approach not only on these surrogate endpoints but
also on the “hard” endpoints, such as the incidence of
major cardiovascular events, vertebral fractures, the ap-
pearance or progression of diabetic complications, mor-
tality, andquality of life. To evaluate this latter parameter,
a specifically designed questionnaire for patients affected
with cortisol excess should be used.
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Finally, to reduce the number of useless adrenal oper-
ations, these studies should also extensively and regularly
(i.e. annually) evaluate the HPA axis activity in AI pa-
tients. These data could provide important information
regarding the most accurate biochemical parameters in
predicting before surgery the benefit of surgery itself. For
these reasons, more reliable methods for measuring cor-
tisol secretion are also needed.
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